Evaluation of effect on the postprandial glucose elevation and glycemic variability of Imeglimin - IMAGINE IMeglimin Amplifies Glucose-stimulated INsulin secretion and modifies glycemic Elevation in type 2 diabetes

Toho university0 sites15 target enrollmentOctober 13, 2022

Overview

No summary available.

Registry

who.int

Start Date

October 13, 2022

End Date

June 30, 2025

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

•(1\)Type 1 diabetes mellitus patients (2\)Patients with severe liver disease or AST (GOT) or ALT (GPT) \>100 IU/L (3\)Patients with serious renal disease and patients with a serum creatinine level of 2\.0 mg/dL or higher before the start of the study (4\)Patients with overt heart failure and those who had myocardial infarction within 3 months before the start of the study (5\)Patients with severe pancreatic disease (6\)Patients with acute stage/serious condition that may cause change in condition due to blood sugar fluctuation or addition of drugs (7\)Patients with serious infections or serious trauma. Patients before and after surgery (8\)Patients with severe chronic bowel disease accompanied by inflammatory bowel disease, colonic ulcer, focal bowel obstruction, bowel obstruction predisposition, or digestive/absorptive disorders (9\) Excessive habitual drinkers (10\) Pregnant women, women who may be pregnant, women who wish to become pregnant, and women who are breastfeeding (11\) Patients who are judged to be inappropriate by the investigator